Antiplatelet therapy and atherosclerotic events. Risks and patients' values need to be included in decision about aspirin for prevention of coronary heart disease

BMJ. 2002 Apr 13;324(7342):917.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aspirin / therapeutic use*
  • Coronary Disease / prevention & control*
  • Humans
  • Patient Selection
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Risk Factors

Substances

  • Platelet Aggregation Inhibitors
  • Aspirin